- Home
- DHAI vs CVM Comparison
DHAI vs CVM Comparison
Compare DHAI & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHAI
- CVM
- Stock Information
- Founded
- DHAI 2007
- CVM 1983
- Country
- DHAI United States
- CVM United States
- Employees
- DHAI N/A
- CVM N/A
- Industry
- DHAI
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DHAI
- CVM Health Care
- Exchange
- DHAI NYSE
- CVM Nasdaq
- Market Cap
- DHAI 49.1M
- CVM 40.1M
- IPO Year
- DHAI N/A
- CVM 1987
- Fundamental
- Price
- DHAI $1.23
- CVM $0.40
- Analyst Decision
- DHAI
- CVM
- Analyst Count
- DHAI 0
- CVM 0
- Target Price
- DHAI N/A
- CVM N/A
- AVG Volume (30 Days)
- DHAI 430.9K
- CVM 2.0M
- Earning Date
- DHAI 11-14-2024
- CVM 01-13-2025
- Dividend Yield
- DHAI N/A
- CVM N/A
- EPS Growth
- DHAI N/A
- CVM N/A
- EPS
- DHAI N/A
- CVM N/A
- Revenue
- DHAI $73,490,000.00
- CVM N/A
- Revenue This Year
- DHAI N/A
- CVM N/A
- Revenue Next Year
- DHAI N/A
- CVM $152.91
- P/E Ratio
- DHAI N/A
- CVM N/A
- Revenue Growth
- DHAI 16.95
- CVM N/A
- 52 Week Low
- DHAI $0.72
- CVM $0.36
- 52 Week High
- DHAI $3.67
- CVM $3.08
- Technical
- Relative Strength Index (RSI)
- DHAI 45.76
- CVM 38.00
- Support Level
- DHAI $1.22
- CVM $0.37
- Resistance Level
- DHAI $1.57
- CVM $0.42
- Average True Range (ATR)
- DHAI 0.33
- CVM 0.04
- MACD
- DHAI -0.05
- CVM -0.00
- Stochastic Oscillator
- DHAI 4.05
- CVM 11.83
About DHAI DIH HOLDINGS US INC
DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.